tpiv100
Vaccineexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2019 (NCT03631043)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06324240 | Phase 1 | Dec 31, 2024 | Emory University, National Cancer Institute (NCI) |
| NCT05419011 | Phase 2 | Nov 1, 2022 | National Cancer Institute (NCI), University of Kansas |
| NCT04639466 | Phase 1 | Dec 23, 2020 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04197687 | Phase 2 | Jan 15, 2020 | Academic and Community Cancer Research United, Mayo Clinic, National Cancer Institute (NCI) |
| NCT03631043 | Early Phase 1 (Phase 1) | Jan 31, 2019 | University of Texas at Houston |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 4 | 1 | 2 | 2020 |
| Academic and Community Cancer Research United | Academic/Hospital | 1 | 1 | 1 | 2020 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Kansas | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
7 organizations
Page 1 / 1